Prognostic importance of PAI-1 in node negative breast cancer patients-Results after 10 years of follow up

Pathology Research and Practice

Volumn 207, Issue 5, 2011, Pages 290-294

  Eljuga, Domagoj ^a   Razumovic, Jasminka Jakic ^a   Bulic, Kresimir ^a   Petrovecki, Marko ^a   Draca, Natasa ^b   Bulic, Suzana Ozanic ^c  

^a KBC Zagreb   (Croatia)

^b Polyclinic Svjetlost ^*  (Croatia)

^c Clinical Hospital Sisters of Mercy   (Croatia)

Author keywords

Breast cancer; Immunohistochemistry; PAI 1; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; CROATIA; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR CELL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CROATIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955478026     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.02.008     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
2. Lonning P.E., Knappskog S., Staalesen V., et al. Breast cancer prognostication and prediction in the postgenomic era. Ann. Oncol. 2007, 18:1293-1306.
3. Borg A., Tandon A.K., Sigurdsson H., et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990, 50:4322-4327.
4. Pennery E. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. Eur. J. Oncol. Nurs. 2008, 12:233-243.
5. Cody H.S., Borgen P.I., Tan L.K. Redefining prognosis in node-negative breast cancer: can sentinel lymph node biopsy raise the threshold for systemic adjuvant therapy. Ann. Surg. Oncol. 2004, 11:227-230.
6. Isaacs C., Stearns V., Hayes D.F. New prognostic factors for breast cancer. Semin. Oncol. 2001, 28:53-67.
7. Harbeck N., Kates R.E., Schmitt M., et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer 2004, 5:348-352.
8. Duffy M.J., O'Grady P., Devaney D., et al. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 1988, 62:531-533.
9. Janicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 1991, 17:303-312.
10. Hansen S., Overgaard J., Rose C., et al. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor. Br. J. Cancer 2003, 88:102-108.
11. Conese M., Blasi F. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanisms and regulation. Biol. Chem. Hoppe. Seyler 1995, 376:143-155.
12. Rijken D.C. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin. Haematol. 1995, 8:291-312.
13. Durand M.K., Bodker J.S., Christensen A., et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb. Haemost. 2004, 91:438-449.
14. Dellas C., Loskutoff D.J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb. Haemost. 2005, 93:631-640.
15. Kortlever R.M., Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 2006, 5:2697-2703.
16. Bianchi E., Cohen R.L., Dai A., et al. Immunohistochemical localisation of the plasminogen activator inhibitor-1 in breast cancer. Int. J. Cancer 1995, 60:597-603.
17. Christensen L., Simonsen A.C.W., Heegaard C.W., et al. Immunohistochemical localisation of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha2-microglobulin receptor in human breast carcinomas. Int. J. Cancer 1996, 66:441-452.
18. Jahkola T., Toivonen T., Smitten K., et al. Urokinase plasminogen activator and type-1 plasmionogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin_c and other factors. Br. J. Cancer 1999, 80:167-174.
19. Swee C.G., Geurts-Moespot J., Grebenschikov N., et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br. J. Cancer 1998, 78:1434-1441.
20. Harris L., Fritsche H., Mennel R., et al. Update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25:5287-5312.
21. Look M.P., Putten W.L.J., Duffy M.J., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 2002, 94:116-128.
22. Ferrier C.M., Witte H.H., Tienoven D.H., et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components oft he plasminogen activation system in human tumour cells. Br. J. Cancer 1999, 79:1534-1541.
23. Janicke F., Schmitt M., Hafter R., et al. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relaps in breast cancer. Fibrinolyisis 1990, 4:69-78.
24. Stephens R.W., Brunner N., Janicke F., et al. The uriokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res. Treat. 1998, 52:99-111.
25. Duffy M.J., Maguire T.M., McDermott E.W., et al. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J. Surg. Oncol. 1999, 71:130-135.
26. Dublin E., Hanby A., Patel N.K., et al. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am. J. Pathol. 2000, 157:1219-1227.
27. Vissecher D.W., Sarker F., LoRusso P., et al. Immunohistologic evaluation of invasion-associated proetins in breast carcinoma. Mod. Pathol. 1993, 6:302-306.